Co-Authors
This is a "connection" page, showing publications co-authored by MARGARET SPITZ and YUANQING YE.
Connection Strength
0.425
-
Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer. 2008 Nov 01; 113(9):2488-95.
Score: 0.083
-
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008 Nov; 18(11):955-65.
Score: 0.083
-
Wnt signaling pathway pharmacogenetics in non-small cell lung cancer. Pharmacogenomics J. 2014 Dec; 14(6):509-22.
Score: 0.031
-
Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014 Jul; 46(7):736-41.
Score: 0.031
-
Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy. Clin Pharmacol Ther. 2014 Sep; 96(3):360-369.
Score: 0.030
-
Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. Clin Cancer Res. 2012 Nov 01; 18(21):5983-91.
Score: 0.027
-
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst. 2011 May 18; 103(10):817-25.
Score: 0.025
-
Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila). 2011 Feb; 4(2):185-93.
Score: 0.024
-
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
Score: 0.024
-
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011 Jan; 71(1):82-8.
Score: 0.023
-
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol. 2010 Apr; 11(4):321-30.
Score: 0.023
-
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009 Jul; 2(7):617-24.
Score: 0.022